Compare Two Anti-Scorpion Venom Serum In Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01415830|
Recruitment Status : Completed
First Posted : August 12, 2011
Last Update Posted : February 7, 2013
The morbidity associated with scorpion sting intoxication presents an endemic pattern in the country, where there are highly venomous species of scorpions so the scorpion sting intoxication (IPPA) is considered a medical emergency.
On the other hand, there is scarce scientific literature from different controlled studies evaluating anti-scorpion serum, considering clinical severity scales, lab results and their safety. The aim of this study is to compare the efficacy and safety of scorpion sting treatment, using two sera, one produced by Birmex versus Alacramyn ® (Bioclon).
|Condition or disease||Intervention/treatment||Phase|
|Scorpion Sting||Biological: Anti-scorpion venom serum Birmex Biological: Anti-scorpion venom serum Alacramyn||Phase 3|
We consider relevant conduct this study because the poisoning scorpion bite represents a public health problem.
This is a randomized clinical trial, which included 120 subjects of both sexes aged 0 and 15 years old and residents of the state of Guanajuato, divided into 2 groups: 60 patients received antiscorpion serum of Birmex and 60 patients receive other commercial serum (Alacramyn).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Randomized Controlled Trial To Evaluate Efficacy And Safety Of The Polyvalent Anti-scorpion Venom Serum Of Birmex Versus Other Commercial Venom Serum In Children Population|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||May 2012|
|Actual Study Completion Date :||May 2012|
Experimental: Anti-scorpion venom serum Birmex
Patients 0 to 15 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
Biological: Anti-scorpion venom serum Alacramyn
The dose may be required fot the patient according to clinical manifestations and evolution
Other Name: antiscorpion venom serum
Active Comparator: Anti-scorpion venom serum Alacramyn
Patients 0 to 15 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
Biological: Anti-scorpion venom serum Birmex
the dose may be required for the patient according to clinical manifestations and evolution
Other Name: anti-scorpion venom serum
- Resolution of signs and symptoms of scorpion envenomation [ Time Frame: after treatment (expected average of 12 hrs) ]
- Evaluate the adverse events in every treated child [ Time Frame: inmediately after treatment and until 5 days later ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01415830
|Hospital General Regional de León|
|León, Guanajuato, Mexico, 37320|
|Principal Investigator:||Ma. Eugenia Jimenez-Corona, PhD||Laboratorios de Biologicos y Reactivos de México SA de CV|